---
title: Candel Therapeutics | Viral Immunotherapy for Cancer
description: Clinical-stage biotech developing viral immunotherapy platforms for solid tumors. Phase 3 results in prostate cancer, active trials in lung and brain cancer.
---

[Skip to content](https://candeltx.com#main-content)

[![Candel Therapeutics Logo](https://candeltx.com/hubfs/logo-main-nav-1.svg "Candel Therapeutics Logo")](https://candeltx.com/?hsLang=en)

- CAN-2409 Mechanism of Action
- CAN-3110 Mechanism of Action
- [ Careers ](https://candeltx.com/careers)
- Investigator Portal

- [ About ](https://candeltx.com/about)
  
  Show submenu for About 
  
    - [ Leadership ](https://candeltx.com/leadership)
- [ Science ](https://candeltx.com/science)
- [ Pipeline ](https://candeltx.com/pipeline)
- [ Patients ](https://candeltx.com/patients)
- [ Providers ](https://candeltx.com/providers)
  
  Show submenu for Providers 
  
    - [ Clinical Trials ](https://candeltx.com/providers/#clinical-trials)
    - [ Investigator Login ](https://candeltx.com/investigator-login)
- [ Media ](https://candeltx.com/media)
- [ Investors ](https://ir.candeltx.com/)
- [ Careers ](https://candeltx.com/careers)
- [ Mail ](https://candeltx.com/contact)

- [ About ](https://candeltx.com/about)
  
  Show submenu for About 
  
    - [ Leadership ](https://candeltx.com/leadership)
- [ Science ](https://candeltx.com/science)
- [ Pipeline ](https://candeltx.com/pipeline)
- [ Patients ](https://candeltx.com/patients)
- [ Providers ](https://candeltx.com/providers)
  
  Show submenu for Providers 
  
    - [ Clinical Trials ](https://candeltx.com/providers/#clinical-trials)
    - [ Investigator Login ](https://candeltx.com/investigator-login)
- [ Media ](https://candeltx.com/media)
- [ Investors ](https://ir.candeltx.com/)
- [ Careers ](https://candeltx.com/careers)
- [ Mail ](https://candeltx.com/contact)

# Off-the-Shelf Immunotherapy **for Solid Tumors**

Engineered viral platforms that activate the immune system to recognize and destroy cancer cells.

- [ Explore Our Science ](https://candeltx.com/science?hsLang=en)
- [ For Patients ](https://candeltx.com/patients?hsLang=en)

## Powerful Outcomes, Preserved Quality of Life

For too long, fighting cancer has meant harsh treatments and diminished quality of life. We believe in a different path.

**Our mission is simple:** to extend and improve lives through cancer immunotherapy innovation, without the toxicity of traditional approaches.

- [ About Candel ](https://candeltx.com/about?hsLang=en)

## Real Results for Real Patients 

![30% Improvement in disease-free survival in prostate cancer](https://candeltx.com/hubfs/Group%203371.webp "30% Improvement in disease-free survival in prostate cancer")

Phase 3 data for our lead therapy,  aglatimagene besadenovec, is demonstrating meaningful outcomes for prostate cancer.

- Eight out of ten patients achieved complete pathological response at two years — significantly higher than standard radiation alone.
- Aglatimagene treatment was well tolerated with minimal serious side effects, preserving quality of life during treatment.
- FDA Fast Track and RMAT Designation granted based on results from 745 patients enrolled under Special Protocol Assessment.

- [ View Clinical Data ](https://candeltx.com/patients/#active-trials)

![30% Improvement in disease-free survival in prostate cancer](https://candeltx.com/hubfs/Group%203371.webp "30% Improvement in disease-free survival in prostate cancer")

## Engineered Viruses. Empowered Immune Systems.

Candel has established two off-the-shelf clinical-stage investigational viral immunotherapies designed to deliver meaningful and durable clinical benefit through individualized immune activation based on novel, genetically modified viral constructs.

- [ Explore Immunotherapy ](https://candeltx.com/science?hsLang=en)

---

![HSV TK gene](https://candeltx.com/hubfs/Group%203398.webp "HSV TK gene")

**aglatimagene besodenovec (aglatimagene or CAN-2409)**

### Gene Therapy Vector with Systemic Impact

![HSV TK gene (1)](https://candeltx.com/hubfs/HSV%20TK%20gene%20(1).webp "HSV TK gene (1)")

Aglatimagene is an adenoviral gene construct encoding HSV-thymidine kinase, injected directly into the tumor. When combined with FDA-approved oral prodrugs, it triggers immunogenic cell death and creates optimal conditions for CD8+ T cell–mediated anti-tumor immunity. 

- aglatimagene Mechanism of Action Video

---

![Nestin promoter: ICP34.5](https://candeltx.com/hubfs/Nestin%20promoter.webp "Nestin promoter: ICP34.5")

**linoserpaturev  or CAN-3110**

### Oncolytic Virus with Tumor Specificity

![Nestin promoter: ICP34.5](https://candeltx.com/hubfs/Nestin%20promoter.webp "Nestin promoter: ICP34.5")

Linoserpaturev is a replication-competent HSV engineered for selective killing of cancer cells while sparing healthy tissue. Controlled by the Nestin promoter, it targets high-grade glioma cells with precision. This tumor-specific approach enables multiple dosing without dose-limiting toxicity.

- [ linoserpaturev Mechanism of Action Video ](https://vimeo.com/822133681)

## Find Your Path

Whether you’re seeking treatment options, clinical evidence, or investment opportunities, we’re here to guide you.

![For Patients](https://candeltx.com/hubfs/Group%203389.svg)

**For Patients** 

### **Your Journey Starts Here**

Hope backed by science. Explore active clinical trials designed to improve survival while maintaining quality of life.

[ Learn More ](https://candeltx.com/patients/#active-trials)

![For Providers](https://candeltx.com/hubfs/Group%203385.svg)

**For Providers** 

### **Evidence-Based ** **Innovation**

Evidence to inform your practice. Review Phase 3 data, safety profiles, and mechanism of action for viral immunotherapy across solid tumors.

[ Investigator Resources ](https://candeltx.com/providers?hsLang=en)

![For Investors](https://candeltx.com/hubfs/Group%203387.svg)

**For Investors** 

### **Clinical Progress, ** **Commercial Potential**

Clinical validation with commercial potential. Review Phase 3 data, BLA readiness, and our multimodal platform approach.

[ Investor Relations ](https://ir.candeltx.com/?_gl=1*wm6f49*_ga*MjEwNTMwMDA1Ny4xNzYyMzU1Mzg1*_ga_8D6FY722M3*czE3NjQ5NzI1MzQkbzM3JGcxJHQxNzY0OTc3OTA0JGo1OSRsMCRoMA..*_ga_SWHZ99VJZD*czE3NjQ5NzI1MzQkbzM3JGcxJHQxNzY0OTc3OTA0JGo1OSRsMCRoMA..)

## Explore

[![Contact](https://no-cache.hubspot.com/cta/default/50530382/interactive-202464911429.png) ](https://candeltx.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIkfdkfu%2FyXe7%2BmlsMPf7AF5TwhzoeEsMAAQD8RVB6SWb6Kh5FJfiPDY%2FEu2VpnC6lmUdaZJIS6AnAGLDx88lMMJxvem70ZefEbGmDYuqxoLcK8woLIEEVBJNtkzm1ujQh1L3ICdeveFPVxWNmMJoy3I1jUJgdD3scXWMsuBv6JPEOoVTOMq60%3D&webInteractiveContentId=202464911429&portalId=50530382&hsLang=en)

- [ About ](https://candeltx.com/careers?hsLang=en)
- [ Patients ](https://candeltx.com/patients?hsLang=en)
- [ Science ](https://candeltx.com/science?hsLang=en)

[![candel logo white](https://candeltx.com/hubfs/logo-footer.svg "candel logo white")](https://candeltx.com/?hsLang=en)

- [ About ](https://candeltx.com/about)
- [ Science ](https://candeltx.com/science)
- [ Pipeline ](https://candeltx.com/pipeline)
- [ Patients ](https://candeltx.com/patients)
- [ Providers ](https://candeltx.com/providers)
- [ Media ](https://candeltx.com/media)
- [ Investors ](https://ir.candeltx.com/)
- [ Contact ](https://candeltx.com/contact)

- [ About ](https://candeltx.com/about)
- [ Science ](https://candeltx.com/science)
- [ Pipeline ](https://candeltx.com/pipeline)
- [ Patients ](https://candeltx.com/patients)
- [ Providers ](https://candeltx.com/providers)
- [ Media ](https://candeltx.com/media)
- [ Investors ](https://ir.candeltx.com/)
- [ Contact ](https://candeltx.com/contact)

© 2026 by Candel Therapeutics